Rob joined Mercia in 2022, with a primary focus of investing our EIS and NPIF funds, predominantly into the North West region. He focusses on making investments into high-growth technology businesses, with a particular interest in those in the Life Sciences, Energy & Utilities, Telecoms, Insurance and Payments markets.
Prior to joining Mercia, Rob was Head of Strategy and M&A at Verastar, a microSME-focussed business services provider backed by Vitruvian Partners, a leading late-stage technology investor. This role saw him lead the Group’s M&A activity across the Telecoms, Energy, Insurance and Payments sectors, whilst also assisting the Board and Vitruvian in setting the strategic direction of the Group. Before that, Rob spent a number of years at Grant Thornton UK LLP in the M&A, Transaction Services and Restructuring teams, advising mid-sized businesses and Private Equity investors on M&A transactions and investments.
Rob holds a Doctorate from the University of Liverpool’s MRC Centre for Drug Safety Science. His research focussed on understanding the mechanisms underlying adverse drug reactions, with the ultimate aim of identifying novel biomarkers of drug-induced liver injury to aid in the development of pharmaceuticals and the diagnosis of liver injury in the clinic.